Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S IBUPROFEN.
ANAPROX DS vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category C
Category D/X
NSAID
NSAID